A Phase II: Safety and Tolerance of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) With Malignancies Involving the CNS
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs DM CHOC PEN (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- Sponsors Dekk-Tec
- 15 Dec 2018 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.
- 15 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
- 20 Sep 2018 New trial record